June 12, 2023 06:42 AM EDT
People
Startups
Cell/Gene Tx

Re­ju­ve­nate Bio shrinks staff, pipeline fo­cus as George Church spin­out eyes 2024 gene ther­a­py IND

Kyle LaHucik

Senior Reporter

Like many oth­er biotechs in this mar­ket en­vi­ron­ment, small gene ther­a­py mak­er Re­ju­ve­nate Bio has strug­gled to re­ju­ve­nate its bank ac­count.

The San Diego start­up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times